BridgeBio Pharma, Inc.
BBIO Healthcare Biotechnology
BridgeBio Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.1 million, up 126.3% from fiscal 2024. In the quarter to June 2026, revenue grew 120.4%, EPS grew 17.9%, free cash flow grew 16.6% and total debt rose 4.22%, each against the same quarter a year earlier.
Follow BBIO
BridgeBio Pharma, Inc. (BBIO) EV/Sales
As of 16 October 2026, BridgeBio Pharma, Inc. (BBIO) trades at a EV/Sales of 19.9×. Over the past ten years it has ranged from 0.0× (December 2020) to 1,223× (July 2023); the current reading is higher than 21% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 31.7× | 14.40% |
| FY2024 | 27.7× | (96.72%) |
| FY2023 | 845× | 2,805.77% |
| FY2022 | 29.1× | (38.14%) |
| FY2021 | 47.0× | (72.21%) |
| FY2020 | 169× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 22.1× | (16.89%) |
| Mar 2026 | 26.6× | (15.95%) |
| Dec 2025 | 31.7× | 0.39% |
| Sep 2025 | 31.6× | (20.11%) |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | 3.4× |
| BMRN BioMarin Pharmaceutical Inc. compare | 4.1× |
| EXEL Exelixis, Inc. compare | 6.1× |
| TECH Bio-Techne Corp compare | 9.3× |
| HALO Halozyme Therapeutics, Inc. compare | 9.7× |
| ASND Ascendis Pharma A/S compare | 11.6× |
| CORT Corcept Therapeutics Incorporated compare | 13.6× |
| BBIO BridgeBio Pharma, Inc. | 19.9× |
| SMMT Summit Therapeutics PLC compare | 15,310× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)